Pharmaceuticals
Antengene Receives Clinical Trial Approval in Australia for Phase I ATTRACT Study of ATG-201 (CD19 x CD3 TCE) in B Cell-related Autoimmune Diseases
SHANGHAI and HONG KONG, Aug. 25, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dis...
2026-08-25 08:30
2399
WuXi XDC Delivers Strong First Half 2026 Performance, with Improving Margins and Profitability Further Strengthening Global ADC/XDC CRDMO Leadership
* Group total revenue increased to RMB 3,701.4 million, representing 37.0% period-over-period growth on an AER[1] basis (41.5% growth on a CER[2] basis) * Gross profit grew by 40.6% period-over-period, reaching RMB 1,371.3 million. Gross profit margin was 37.0%, a 0.9 percentage points increas...
2026-08-24 20:35
3462
ImmunoForge Selected for the Ministry of SMEs and Startups' 'Global TIPS R&D' Program… "Expansion of the LMT Platform"
* Development of Leptin receptor-based technology and hybrid LNP platform * Combining Blood-Brain Barrier penetration and a one-month sustained-release formulation in a single structure, with potential applications in CNS-targeted therapeutics * Technology validated by winning first place in...
2026-08-24 15:01
1900
INDONESIAN HEALTHCARE TRAVEL TO MALAYSIA HITS RECORD RM2.2 BILLION AS MHX RETURNS TO YOGYAKARTA
YOGYAKARTA, Indonesia, Aug. 24, 2026 /PRNewswire/ -- Malaysia Healthcare Travel Council (MHTC) once again strengthened Malaysia's presence in Indonesia through MHX Yogyakarta 2026, held from 20 to 23 August 2026 at the Grand Atrium, Pakuwon Mall Jogja. The four-day event came on the back of a rec...
2026-08-24 13:31
2781
Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy
* HM17321, a proprietary UCN2 (urocortin-2) analog, is being developed as a treatment for chronic-weight management and associated conditions, including obesity * Total deal value of up to $2.3 billion, including upfront, milestone payments and tiered royalties based on net sales SEOUL, South...
2026-08-24 12:40
2069
Pulnovo Medical Announces First Two U.S. Patients Enrolled in PULSE-LHD IDE Clinical Trial of Pulmonary Artery Denervation in Treating Pulmonary Hypertension Associated with Left Heart Disease
NEW YORK, Aug. 23, 2026 /PRNewswire/ -- Pulnovo Medical, a globally recognized pioneer in medical devices for pulmonary hypertension (PH) and heart failure (HF), today announced the enrollment of the first two patients in its PULSE-LHD clinical trial, conducted under a U.S. Food and Drug Administ...
2026-08-24 11:05
2185
Rznomics Joins Lilly Gateway Labs in San Diego to Accelerate RNA Therapeutics
SEONGNAM, South Korea, Aug. 23, 2026 /PRNewswire/ -- Rznomics Inc.(KOSDAQ: 476830), a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced that it is joining Lilly Gateway Labs (LGL) in San Diego, California. Lilly Gateway Labs is a best-in-class innov...
2026-08-24 09:54
4629
Antengene Announces 2026 Interim Results: Achieves First‑Ever Profitability and Accelerates Value Creation Through Innovative R&D
SHANGHAI and HONG KONG, Aug. 24, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dis...
2026-08-24 09:00
3741
Anbogen Therapeutics and The University of Tokyo Enter Collaborative Research Agreement to Evaluate ABT-301 Across Multiple Tumor Types, Targeting Accelerated Human Clinical Indication Expansion
TAIPEI, Aug. 24, 2026 /PRNewswire/ -- Anbogen Therapeutics Inc. (TPEx: 7784) ("Anbogen" or the "Company"), a clinical-stage precision oncology company, today announced that it has entered into a Collaborative Research Agreement (CRA) with the Laboratory of Veterinary Surgery, Graduate School of ...
2026-08-24 08:00
2042
Henlius Reports 2026 Interim Results: Sustained Profitability Leap, Advancing Global Value Validation
SHANGHAI, Aug. 21, 2026 /PRNewswire/ -- On August 21, Henlius (2696.HK) announced its interim results for the 2026 fiscal year. During the reporting period, the company showcased strong organic growth momentum and sustainable earnings generation, with revenue reaching RMB 3.5882 billion, a 27.3% ...
2026-08-21 21:50
19362
CureGene Completes First‑Participant Dose in Phase I Trial of CG‑0416, Advancing Clinical Development of Novel Oral Liver-Targeting THR-β Agonist
SHANGHAI, Aug. 21, 2026 /PRNewswire/ -- CureGene recently announced that the first subject has been dosed in its Phase I clinical trial of CG-0416, a novel oral liver-targeting THR-β agonist developed in-house, in Australia. Subject enrollment is progressing smoothly. CG-0416 is designed based o...
2026-08-21 20:08
17149
China's Personalized mRNA Cancer Therapy Sector Accelerates: How Far Is It From a "DeepSeek Moment"?
BEIJING, Aug. 21, 2026 /PRNewswire/ -- Personalized mRNA cancer therapy has recently reached an important milestone. An international Phase 3 study in high-risk melanoma reported positive results, further supporting the clinical potential of personalized neoantigen therapy and drawing renewed att...
2026-08-21 17:28
2219
Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) NDA Accepted by NMPA, Poised to Become World's First Approved 4-1BB-Targeting Therapy
NANJING, China, Aug. 21, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for Op...
2026-08-21 17:20
2826
Dizal to Present Emerging Data on ZEGFROVY® in Non-Small Cell Lung Cancer at WCLC 2026
SHANGHAI, Aug. 21, 2026 /PRNewswire/ -- Dizal (SSE: 688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced today that the latest clinical data on its novel epidermal growth factor receptor (EGFR) inhibitor ZE...
2026-08-21 16:03
2751
3S Bio Announces 2026 Interim Results: Innovation-Driven, Win-Win Collaboration, and Sustainable Growth
SHANGHAI, Aug. 21, 2026 /PRNewswire/ -- 3S Bio (01530.HK) today announced its interim results for the first half of 2026. During the period, the Company recorded revenue of RMB 4.53 billion, representing a year-over-year growth of 3.9%. Net profit attributable to equity holders of the Company rea...
2026-08-21 15:39
6369
Sunshine Guojian Releases 2026 Interim Report:
Innovation-driven, Steady Advancement SHANGHAI, Aug. 21, 2026 /PRNewswire/ -- Today, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (hereinafter referred to as "Sunshine Guojian", stock code: 688336.SH), a pioneer in China's antibody therapeutics, released its 2026 interim report. In the f...
2026-08-21 08:00
4671
Brii Biosciences Provides Corporate Updates and Reports 2026 Interim Financial Results
Topline Data from Phase 2b Studies Inform HBV Functional Cure Strategy; Additional Data Expected in 2H 2026 Emerging Discovery Programs Build Momentum BRII-5395 mRNA Cancer Vaccine Moving into Clinical Evaluation for HCC Strong Cash Position Supports Continued Strategic Execution Conference Cal...
2026-08-21 07:10
5066
inFlow Inventory launches lot number and expiry date tracking
Small manufacturers and distributors in food, beverage, pharmaceutical and medical device industries can now trace any batch from receipt to customer, at a fraction of the cost of an enterprise ERP. TORONTO, Aug. 21, 2026 /PRNewswire/ -- inFlow Inventory has launched lot number and expiry date ...
2026-08-20 23:31
2359
Apollo Hospitals launches 'Always Open, Always Here', a global first in healthcare from India
NEW DELHI, Aug. 20, 2026 /PRNewswire/ -- Apollo Hospitals launched 'Always
Open. Always Here.', a first-of-its-kind initiative that makes routine and
planned healthcare services available across all seven days of the week,
including Sundays.
2026-08-20 22:11
2374
Matwings Demonstrates Closed-Loop Protein AI Through Four AI-Wet Lab Cycles and 222 Protein Variants
The GenSci148 program illustrates a shift from one-time mutation prediction to iterative protein engineering under real drug-development constraints SHANGHAI, Aug. 20, 2026 /PRNewswire/ -- Shanghai Matwings Technology Co., Ltd. ("Matwings") today announced that GenSci148 Injection, an investigati...
2026-08-20 19:00
1656
Week's Top Stories
Most Reposted
TD Brings its Global Asset Management Businesses Under One Name
[Picked up by 1168 media titles]
2026-11-02 20:00OceanaGold Reports Third Quarter 2026 Results
[Picked up by 1129 media titles]
2026-11-05 06:52Overstory Launches Integrated AI Platform to Deliver First Living Model of Grid Risk
[Picked up by 1082 media titles]
2026-11-03 22:00Fintech OPay Raises $304 Million Ahead of NYSE Debut: NYSE Content Update
[Picked up by 1079 media titles]
2026-10-30 22:34
H.E. Ahmed Al-Khateeb, Saudi Minister of Tourism, Inaugurates Saudi Land at WTM London 2026, Reinforcing Saudi's Commitment to Global Travel Trade
[Picked up by 1067 media titles]
2026-11-04 07:31
Most Read
1B views since June: Coda and TikTok Gaming turn content into commerce
2026-11-02 09:35
62840
Airbrush Upgrades AI Image Enhancer With 16K Output and Batch Processing for Up to 50 Images
2026-11-03 02:00
58984
iQIYI Launches China's First AI Film Studio in Shanghai, with Inaugural Title "Cop in Trouble" in Production
2026-11-02 09:52
55956
Korean Derma Skincare Brand MDP+ Launches at Nordstrom
2026-11-03 00:30
25437
